Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태헌 | * |
dc.date.accessioned | 2016-08-29T12:08:02Z | - |
dc.date.available | 2016-08-29T12:08:02Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 0022-4790 | * |
dc.identifier.issn | 1096-9098 | * |
dc.identifier.other | OAK-18991 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231705 | - |
dc.description.abstract | Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: Atotal of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. (C) 2016 Wiley Periodicals, Inc. | * |
dc.language | English | * |
dc.publisher | WILEY-BLACKWELL | * |
dc.subject | hepatocellular carcinoma | * |
dc.subject | primovist-enhanced magnetic resonance imaging | * |
dc.subject | Barcelona clinic liver cancer | * |
dc.subject | liver dynamic computed tomography | * |
dc.title | Clinical Effect of Add-On Primovist-Enhanced Magnetic Resonance Imaging on Preoperative Tumor Staging in Hepatocellular Carcinoma Patients | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 114 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 106 | * |
dc.relation.lastpage | 111 | * |
dc.relation.journaltitle | JOURNAL OF SURGICAL ONCOLOGY | * |
dc.identifier.doi | 10.1002/jso.24272 | * |
dc.identifier.wosid | WOS:000383777600018 | * |
dc.identifier.scopusid | 2-s2.0-84976587401 | * |
dc.author.google | Jin, Young-Joo | * |
dc.author.google | Lee, Jin-Woo | * |
dc.author.google | Kwon, Oh Sang | * |
dc.author.google | Jung, Young Kul | * |
dc.author.google | Kwon, Jung Hyun | * |
dc.author.google | Jang, Jeong Won | * |
dc.author.google | Kim, Young Seok | * |
dc.author.google | Kim, Tae Hun | * |
dc.author.google | Jeon, Yong Sun | * |
dc.contributor.scopusid | 김태헌(57125156300;57219781484) | * |
dc.date.modifydate | 20240422114851 | * |